Loading clinical trials...
Loading clinical trials...
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
Conditions
Interventions
eribulin mesylate + erlotinib
eribulin mesylate + erlotinib
Locations
64
United States
Bessemer, Alabama, United States
Birmingham, Alabama, United States
Beverly Hills, California, United States
La Jolla, California, United States
Aurora, Colorado, United States
Boulder, Colorado, United States
Start Date
February 22, 2010
Primary Completion Date
April 7, 2011
Completion Date
January 18, 2017
Last Updated
June 22, 2023
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT06253871
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions